Sacituzumab govitecan for Breast Cancer User Reviews

Brand names: Trodelvy

Sacituzumab govitecan has an average rating of 8.3 out of 10 from a total of 3 reviews for the treatment of Breast Cancer. 100% of reviewers reported a positive experience, while 0% reported a negative experience.

Sacituzumab govitecan rating summary

8.3 average rating out of 10

3 ratings from 4 user reviews.

Compare all 185 medications used in the treatment of Breast Cancer.

10		0%
9		33%
8		67%
7		0%
6		0%
5		0%
4		0%
3		0%
2		0%
1		0%

Ell...
February 5, 2024

Trodelvy (sacituzumab govitecan) "Other than neutropenia and alopecia, my side effects are minimal. I'm in the middle of my treatment plan, still hopeful that this will give me a sustained remission."

8 / 10

Was this helpful?Yes No

2 Report

Jan...
Taken for 1 to 6 months
January 19, 2024

Trodelvy (sacituzumab govitecan) "I occasionally have slurred speech and difficulty swallowing. It's kind of intermittent. No other side effect except complete alopecia"

8 / 10

Was this helpful?Yes No

2 Report

Sta...
Taken for 1 to 6 months
April 24, 2024

Trodelvy (sacituzumab govitecan) "Horrible paralyzing bone pain. Horrible constipation or diarrhea. Horrible experience. Also, face numbness."

Was this helpful?Yes No

0 Report

sil...
Taken for 6 months to 1 year
December 5, 2024

Trodelvy (sacituzumab govitecan) "It helped to have good PET scans and to shrink tumors in my chest."

9 / 10

Was this helpful?Yes No

0 Report

Reviews may be edited to correct grammar/spelling or to remove inappropriate language and content. Reviews that appear to be created by parties with a vested interest are not published. This information is not intended to endorse any particular medication. While these reviews may be helpful, they are not a substitute for the expertise, knowledge, and judgement of healthcare professionals.